http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0043392-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b172e4dc6f8b115773eb99a04e8260f6
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-10
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-10
filingDate 2000-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_535f5ebccd55ef0fc95a6ec557fb92a8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d88412338ddca1142937de38ef6a285
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5b13c80bad3a7f34237ca83d10d4ae80
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e16ea5fb9c0f6f9b3978a5335f10744c
publicationDate 2000-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-0043392-A3
titleOfInvention Use of imidazo[1,5-a]-pyrido[3,2-e]-pyrazinones as medicaments
abstract The invention relates to the use of imidazo[1,5-a]-pyrido[3,2-e]-pyrazinones of formula (1) as inhibitors for phosphodiesterase 5 for the therapy of erectile dysfunction (impotence). The invention also relates to the use of imidazo[1,5-a]-pyrido[3,2-e]-pyrazinones of formula (1) as dual inhibitors of phosphodiesterase 3 and of phosphodiesterase 5 for the therapy of heart failure, pulmonic hypertonia and vascular diseases which are accompanied by insufficient blood supply. The invention further relates to a method for making the same.
priorityDate 1999-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0400583-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5723463-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-19510965-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID411298829
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID227266714
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID56988399
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID66876768
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID227266713

Total number of triples: 37.